$SHC Cashflow Statement | Understand Stock

$SHC

$18.49 +$0.10 (0.54%) Close

$SHC Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities:
Net income (loss)
Net income
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation
Amortization of intangible assets
Impairment of long-lived assets
Loss on refinancing of debt
Impairment of investment in unconsolidated affiliate
Loss on extinguishment of debt
Deferred income taxes
Share-based compensation expense
Accretion expense
Unrealized foreign exchange loss (gain)
Unrealized gain on embedded derivative instruments
Unrealized (gain) loss on derivatives not designated as hedging instruments
Amortization of debt issuance costs
Other
Changes in operating assets and liabilities:
Accounts receivable
Inventories
Other current assets
Accounts payable
Accrued liabilities
Litigation settlement
Illinois EO litigation settlements
Georgia EO litigation settlement
Litigation settlement
Illinois EO litigation settlements
Georgia EO litigation settlement
Total litigation settlement

Litigation settlement
Illinois EO litigation settlements
Georgia EO litigation settlement
Income taxes payable / receivable, net
Other liabilities
Other long-term assets

Net cash provided by (used in) operating activities
Investing activities:
Purchases of property, plant and equipment
Purchase of Iotron Industries Canada, Inc., net of cash acquired
Purchase of BioScience Laboratories, LLC, net of cash acquired
Purchase of mandatorily redeemable noncontrolling interest in Nelson Laboratories Fairfield, Inc.
Cash acquired
Other investing activities
Net cash used in investing activities

Financing activities:
Dividends and distributions to shareholders
Proceeds from long-term borrowings
Proceeds from issuance of common stock, net of underwriting discounts and issuance costs
Repurchase of common shares
Payment of revolving credit facility
Purchase of noncontrolling interests in China subsidiaries
Payments of debt issuance costs and debt discount
Payments of long-term borrowings
Buyout of leased facility
Shares withheld for employee taxes on equity awards
Other financing activities
Net cash (used in) provided by financing activities

Effect of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents, including restricted cash
Cash and cash equivalents, including restricted cash, at beginning of period
Cash and cash equivalents, including restricted cash, at end of period
Supplemental disclosures of cash flow information:
Cash paid during the period for interest
Cash paid during the period for income taxes, net of tax refunds received
Purchases of property, plant and equipment included in accounts payable

Comments